Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
All content for Lean By Design is the property of Oscar Gonzalez & Lawrence Wong and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
0112. Safeguarding Scientific Progress with a Maintenance Master Plan.
Lean By Design
37 minutes
1 year ago
0112. Safeguarding Scientific Progress with a Maintenance Master Plan.
Send us a text - Highlight the critical importance of a robust asset management strategy. - Discuss maintenance scheduling, coordination, and the power of clear communication. - Emphasize post-service rituals to ensure optimal equipment performance. - Share personal experiences and lessons learned from overlooked maintenance. - Advocate for dialogue among technicians, scientists, and coordinators. - Dive deep into mastering equipment maintenance for lab resilience and efficiency. Thank you t...
Lean By Design
Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
